Abstract

PROSPECTIVE RANDOMISED STUDY OF HOMOCYSTEINE LOWERING VITAMINS IN SEVERE CARDIOVASCULAR DISEASES

Anusreeraj R. S.*, Divya V. and Adarsh R.

Abstract

Elevated plasma total homocysteine has been identified as an independent risk factor for vascular disease. Our study aim is to analyse the risk of total homocysteine levels for cardiovascular disease and to estimate the potential reduction of cardiovascular disorders mortality by increasing homocysteine lowering vitamins intake. in order to assess efficacy of plasma total homocysteine levels (fasting), 9 CVD patients were randomly assigned and provided with folic acid (5mg), methylcobalamine (500 mcg), pyridoxine (10 mg) All the patients were treated for 3 weeks and fasting totalHCY were measured before and after treatment. 3 healthy volunteers served as normal control group of study. in our randomised study, after administration of folic acid alone in group 1 results in a mean reduction of level o totalHCY f 3.8mol /L and folic acid and methylcobalamine in group 11 produced a mean reduction of 3.8mol/L and folic acid and methylcobalamine in group 11 produced a mean reduction of Thcy level 6.7mol/L. while in group 111, by co-administration of folic acid, methylcobalamine and pyridoxine results in in a significant mean reduction of 7.1mol/L implies the significant of folic acid, methylcobalamine, pyridoxine as homocysteine lowering vitamins. Lowering serum concentration of homocysteine has been proven to reduce the risk of adverse cardiovascular events among peoples. our study supports the co-administration of folic acid, methylcobalamine and pyridoxine as homocysteine lowering vitamins in cardiovascular disease. This method could be a therapeutic strategy to combat the risk of cardiovascular disease.

Keywords: Total homocysteine, methylcobalamine, pyridoxine.